Table 1.

Patient characteristics, laboratory values, ECMO and hospital course and outcome.

Patient Number	1	2	3	4	5	6	7	8	9
Age (yrs.)	22	53	28	27	46	68	26	66	24
Sex	M	F	F	F	M	M	F	M	M
COVID-19 vaccination status	None	None	None	None	None	None	JJ Vaccine*	None	None
CRP (mg/dL)	53.9	26.3	23	4.9	14.6	12.9	2.1	52.1	24.8
ESR (mm/hr)	N/A	9	N/A	27	17	26	2	67	N/A
Peak Troponin T (ng/mL)	0.201	9.9	4.3	5.6	<0.01	12.16	1.34	2.08	1.88
Cardiac Arrest	PEA arrest	No	PEA arrest	No	No	No	PEA arrest	VF/VT arrest	VF arrest
LVEF	25%	EF 5%	36%	22%	8%	20%	10%	10%	15%
Duration of VA ECMO	5 days	9 days	5 days	10 days	6 days*	2 days	9 days	8 days	7 days
Survival to Discharge	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes
COVID-19 treatment	Steroid, remdesivir	Steroid, remdesivir, convalescent plasma	Steroid, remdesivir, tocilizumab, IVIG	Steroid, remdesivir, IVIG	Steroid, IVIG, remdesivir	Steroid	Steroid	Steroid	Steroid
Post ECMO LVEF	55%	45%	55%	55%	30%	N/A	55%	50%	57%
Total Hospital LOS	15 days	35 days	104 days	56 days	27 days	2 days	50 days	35 days	17 days
ICU LOS	9 days	16 days	104 days	38 days	27 days	2 days	34 days	35 days	11 days

Sex: M = Male; F = Female; ESR Erythrocyte Sedimentation Rate; CRP: C reactive Protein.

JJ Vaccine – Johnson and Johnson Vaccine received 6 months prior to fulminant myocarditis in this patient.

PEA, pulseless electrical activity; VT, pulseless ventricular tachycardia; VF, ventricular fibrillation.

ICU, intensive care unit; LOS, length of stay; LVEF; left ventricle ejection fraction.